Skip to main content

Alnylam CEO: Novartis' cuts to RNAi a 'miserable predictor' of success

A decision by drug giant Novartis to cut back on its research into a field of drugs known as RNA interference has been cited as spurring a selloff at Cambridge biotech Alnylam Pharmaceuticals...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.